Clinical course and treatment of anti-HMGCR antibody–associated necrotizing autoimmune myopathy
Citation Manager Formats
Make Comment
See Comments

Abstract
Objective: We examined a cohort of Australian patients with statin exposure who developed a necrotizing autoimmune myopathy (NAM) associated with a novel autoantibody against 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) and describe the clinical and therapeutic challenges of managing these patients and an optimal therapeutic strategy.
Methods: Clinical, laboratory, EMG, and histopathologic results and response to immunomodulation are reported in 6 Australian patients with previous statin exposure and antibodies targeting HMGCR.
Results: All patients presented with painless proximal weakness following statin therapy, which persisted after statin cessation. Serum creatine kinase (CK) levels ranged from 2,700 to 16,200 IU/L. EMG was consistent with a myopathic picture. Muscle biopsies revealed a pauci-immune necrotizing myopathy. Detailed graphical representation of the clinical course of these patients showed a close association with rising CK and an increase in clinical weakness signifying relapses, particularly upon weaning or ceasing steroids. All 6 patients were responsive to initial steroid therapy, with 5 relapsing upon attempts to wean steroids. Both CK and clinical strength improved with the reinstitution of immunotherapy, in particular steroids and IV immunoglobulin (IVIg). All patients required treatment with varying multiagent immunosuppressive regimens to achieve clinical remission, including prednisone (n = 6), IVIg (n = 5), plasmapheresis (n = 2), and additional therapy including methotrexate (n = 6), cyclophosphamide (n = 2), rituximab (n = 2), azathioprine (n = 1), and cyclosporine (n = 1).
Conclusions: Recognition of HMGCR antibody–associated NAM is important because these patients are responsive to immunosuppression, and early multiagent therapy and a slow and cautious approach to withdrawing steroids may improve outcomes.
GLOSSARY
- CK=
- creatine kinase;
- DM=
- dermatomyositis;
- HMGCR=
- 3-hydroxy-3-methylglutaryl-coenzyme A reductase;
- IVIg=
- IV immunoglobulin;
- MHC=
- major histocompatibility complex;
- NAM=
- necrotizing autoimmune myopathy;
- PM=
- polymyositis
Footnotes
Funding information and disclosures are provided at the end of the article. Go to Neurology.org/nn for full disclosure forms. The Article Processing Charge was paid by the authors.
Supplemental data at Neurology.org/nn
- Received August 24, 2014.
- Accepted in final form January 20, 2015.
- © 2015 American Academy of Neurology
This is an open access article distributed under the terms of the Creative Commons Attribution-Noncommercial No Derivative 3.0 License, which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Babak Hooshmand and Dr. David Smith
► Watch
Alert Me
Recommended articles
-
Article
Inflammatory myopathy with myasthenia gravisThymoma association and polymyositis pathologyNaohiro Uchio, Kenichiro Taira, Chiseko Ikenaga et al.Neurology: Neuroimmunology & Neuroinflammation, December 24, 2018 -
Article
Cancer association as a risk factor for anti-HMGCR antibody-positive myopathyMasato Kadoya, Ayumi Hida, Meiko Hashimoto Maeda et al.Neurology: Neuroimmunology & Neuroinflammation, October 07, 2016 -
Article
Overlapping features of polymyositis and inclusion body myositis in HIV-infected patientsThomas E. Lloyd, Iago Pinal-Fernandez, E. Harlan Michelle et al.Neurology, March 10, 2017 -
Article
High-dose cyclophosphamide without stem cell rescue in immune-mediated necrotizing myopathiesChristopher A. Mecoli, Arash H. Lahouti, Robert A. Brodsky et al.Neurology: Neuroimmunology & Neuroinflammation, July 11, 2017